Effect of Riluzole on MK-801 and Amphetamine-Induced Hyperlocomotion

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Neuropsychobiology

• Publication date

  2003-07-01

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1159/000071825PMID 12886037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats

  2005cited by this paper
• Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment

  2001cited by this paper
• Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

  2000cited by this paper
• Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes.

  2000cited by this paper
• Effects of riluzole on electrically evoked neurotransmitter release

  2000cited by this paper
• A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.

  2000cited by this paper
• Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice

  2000cited by this paper
• Interactive effects of subanesthetic ketamine and haloperidol in healthy humans

  1999cited by this paper
• The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat.

  1999cited by this paper
• Clozapine plus lamotrigine in treatment-resistant schizophrenia.

  1999cited by this paper
• Riluzole, a glutamate release inhibitor, and motor behavior

  1998cited by this paper
• Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

  1998cited by this paper
• Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

  1997cited by this paper
• Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats.

  1997cited by this paper
• Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers.

  1997cited by this paper
• A confirmatory dose-ranging study of riluzole in ALS

  1996cited by this paper
• The pharmacology and mechanism of action of riluzole

  1996cited by this paper
• Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors

  1995cited by this paper
• Effects of riluzole (2‐amino‐6‐trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems

  1992cited by this paper
• Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists.

  1982cited by this paper

• Positive allosteric modulator of GLT-1 reduces methamphetamine hyperlocomotion, sensitization and conditioned place preference in mice

  2025cites this paper
• Troriluzole inhibits methamphetamine place preference in rats and normalizes methamphetamine-evoked glutamate carboxypeptidase II (GCPII) protein levels in the mesolimbic pathway.

  2022cites this paper
• Hippocampal Hyperactivity as a Druggable Circuit-Level Origin of Aberrant Salience in Schizophrenia

  2020cites this paper
• Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial

  2018cites this paper
• Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression

  2017cites this paper
• Modeling psychiatric disorders for developing effective treatments

  2015cites this paper
• The emerging role of dopamine–glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment

  2014cites this paper
• Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.

  2014cites this paper
• A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia

  2013cites this paper
• Novel routes to bipolar disorder drug discovery

  2013cites this paper
• Effects of MK-801 and amphetamine treatments on allergic lung inflammatory response in mice.

  2013cites this paper
• Novel glutamatergic agents for major depressive disorder and bipolar disorder.

  2012cites this paper
• Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines.

  2012cites this paper
• Behavioral neurobiology of bipolar disorder and its treatment

  2011cites this paper
• Potential novel therapeutics for bipolar disorders.

  2011cites this paper
• Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments

  2011cites this paper
• The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders.

  2011cites this paper
• Novel Therapeutic Approaches for Treating Bipolar Disorder

  2011cites this paper
• Participação glutamatérgica nos efeitos induzidos pela anfetamina na resposta inflamatória alérgica pulmonar de camundongos

  2011cites this paper
• Development of Brain Monoaminergic Systems

  2011cites this paper
• Glutamatergic modulators: the future of treating mood disorders?

  2010cites this paper
• New Therapeutic Targets for Mood Disorders

  2010cites this paper
• Novel Therapeutic Strategies for Bipolar Disorder

  2010cites this paper
• Potential novel treatments for bipolar depression

  2009cites this paper
• Putative Drugs and Targets for Bipolar Disorder

  2009cites this paper
• Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

  2009cites this paper
• Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder.

  2008cites this paper
• Riluzole and D-amphetamine interactions in humans.

  2008cites this paper
• Bipolar disorder: candidate drug targets.

  2008cites this paper
• Role of glutamate in schizophrenia: integrating excitatory avenues of research

  2008cites this paper
• Riluzole in psychiatry: a systematic review of the literature

  2008cites this paper
• Biological Treatments for Amfetamine Dependence

  2007cites this paper
• A simple webcam-based approach for the measurement of rodent locomotion and other behavioural parameters.

  2006cites this paper
• The Alkaloid Alstonine: A Review of Its Pharmacological Properties

  2006cites this paper
• Sistemas dopaminérgicos e ação antipsicótica: abordagens experimentais e teóricas

  2005cites this paper
• Uses of Ketamine Anesthesia and Analgesia the Neurobehavioral Pharmacology of Ketamine: Implications for Drug Abuse, Addiction, and Psychiatric Disorders

  year unknowncites this paper